BridgeBio: Biotech inspired by Andrew Lo gets treatment FDA approved

This story is available exclusively to Insider subscribers.
Become an Insider and start reading now.
The FDA approved BridgeBio's first drug, for a disease that affects 100 children in the US and Europe.
BridgeBio mitigates risk with a "hub-and-spoke" model, with a central management team and subsidiaries.
The model is gaining in popularity in biopharma and could reshape drug R&D, McKinsey & Co. says.
It wasn't that long ago that the idea behind BridgeBio drew laughter from biotech and finance experts. 
But these days, CEO Neil Kumar says he's taking calls from industry insiders interested in launching companies emulating the BridgeBio model. If it helps patients, he's willing to guide rivals. 

Related Keywords

,Neil Kumar ,Mckinsey Co ,Drug Administration ,Centessa Pharmaceuticals ,Flagship Pioneering ,Bruce Booth ,Alto Based Bridgebio ,Nature Biotechnology ,Third Rock ,Eidos Therapeutics ,Fda Approval ,Biotech ,Venture Capital ,Product Launch ,Ceo Interview ,Drug Approval ,Bi Prime ,Bridgebio ,Dispensed ,Allison Deangelis ,நீல் குமார் ,மகிந்ஸீ இணை ,காயங்கள் சாவடி ,இயற்கை உயிரி தொழில்நுட்பவியல் ,மூன்றாவது பாறை ,ஃப்ட ஒப்புதல் ,பயோடெக் ,துணிகர மூலதனம் ,ப்ராடக்ட் ஏவுதல் ,சிஇஓ நேர்காணல் ,மருந்து ஒப்புதல் ,இரு ப்ரைம் ,